CVS Allergy Relief Fexofenadine Tablets Recalled for Impurity Specifications
Perrigo Company is recalling CVS Allergy Relief Fexofenadine Hydrochloride 180 mg tablets due to an out-of-specification impurity result found during stability testing. The recall affects one lot distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class II recall. The source text does not report any illnesses, injuries, or deaths. The hazard is a quality specification failure detected during routine testing with no evidence of actual harm to consumers, making this a precautionary recall.
Plain-English summary
Perrigo Company PLC is recalling CVS Allergy Relief, Fexofenadine Hydrochloride Tablets, 180 mg, 24-hour antihistamine, in 30-count bottles due to failed impurities and degradation specifications. During stability testing, Lot #1DV1855 (expiration 4/1/2022) was found to have an out-of-specification result for an identified impurity.
The affected product was distributed nationwide in the United States. Consumers who have purchased this product should stop using it and consult with their pharmacist or healthcare provider regarding their options.
No illnesses or injuries have been reported in connection with this recall. The product is identified as NDC 69842-698-39 and UPC 0 50428 62564 4.
The recalled product
- Product
- CVS Allergy Relief, Fexofenadine Hydrochloride Tablets, 180 mg Antihistamine, 24HR, 30 count bottle, NDC 69842-698-39, UPC 0 50428 62564 4
- Manufacturer
- Perrigo Company PLC
- Category
- Drug — Antihistamine Tablets
- Hazard
- impurity
- degradation
- out-of-specification
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 1DV1855
- exp 4/1/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27